SOTYKTU 6 mg film-coated tablets clinical trials
4 indexed studies · 0 currently recruiting
- Ongoing, recruitingTherapeutic exploratory (Phase II)
A randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety deucravacitinib in patients with chronic hand eczema
This study is testing a new unapproved medicine called deucravacitinib for people with long-lasting hand eczema. We want to see if it helps reduce the eczema and if it's safe to use, compared to a dummy pill.
For: Chronic Hand EczemaGermany - Ongoing, recruitingTherapeutic use (Phase IV)
Immunological and functional characteristics of T memory-like cells in psoriasis under treatment with deucravacitinib - IM011-1115
This study looks at how a new medicine, SOTYKTU, affects certain immune cells (TRM-like cells) in people with plaque psoriasis. Researchers want to see if SOTYKTU helps reduce these cells and their activity over 24 weeks to understand how it treats psoriasis.
For: Plaque PsoriasisGermany - Ongoing, recruitingTherapeutic use (Phase IV)
A Mono-Center, Prospective Biomarker Study to investigate the differences in the inflammatory gene expression signature, the distribution of immune cells, psoriasis-driving factors and signaling molecules between classic and hard-to-treat psoriasis plaques and the effects of TYK2 blockade with deucravacitinib – MED-PSO
This study looks at how a new medicine, SOTYKTU, affects moderate to severe plaque psoriasis. Researchers want to understand if it changes how certain genes work and how immune cells behave in different types of psoriasis patches, especially those that are usually hard to treat.
For: moderate to severe plaque psoriasisGermany - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase 3, Randomized, Multicenter, Double-Blind Trial to Evaluate the Efficacy, Safety, and Tolerability of Zasocitinib (TAK-279) Compared to Deucravacitinib in Participants With Moderate-to-Severe Plaque Psoriasis
This study is testing a new medicine, Zasocitinib (TAK-279), for people with moderate to severe plaque psoriasis. It compares it to an existing medicine, Deucravacitinib (SOTYKTU), and a dummy pill to see how well it works, if it's safe, and how people tolerate it.
For: Moderate to Severe Plaque PsoriasisCzechia · France · Bulgaria